Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human BRAF Antibodies:
anti-Rat (Rattus) BRAF Antibodies:
anti-Mouse (Murine) BRAF Antibodies:
Go to our pre-filtered search.
Human Polyclonal BRAF Primary Antibody for FACS, WB - ABIN1881118
Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003
Show all 6 Pubmed References
Human Monoclonal BRAF Primary Antibody for IHC, ELISA - ABIN1724658
Rapp, Goldsborough, Mark, Bonner, Groffen, Reynolds, Stephenson: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. in Proceedings of the National Academy of Sciences of the United States of America 1983
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody for IHC, ELISA - ABIN965693
Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. in Annals of surgery 2006
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody for ICC, IHC - ABIN968991
Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Show all 2 Pubmed References
Human Monoclonal BRAF Primary Antibody for PLA, ELISA - ABIN513800
Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. in Molecular & cellular proteomics : MCP 2013
Human Polyclonal BRAF Primary Antibody for ELISA, IHC (p) - ABIN5573331
Wiggans, Reilly, Kass, Maggs: Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. in Veterinary ophthalmology 2016
Human Polyclonal BRAF Primary Antibody for DB - ABIN389897
Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004
Show all 3 Pubmed References
Mutated Liquid-based FNAs BRAF, N/HRAS (show HRAS Antibodies) and TERT (show TERT Antibodies) mutations were significantly associated with malignancy regardless of the cytological classification
our study suggests that an activating BRAF I463T mutation was associated with eosinophilic cystitis. Importantly, analysis of ctDNA obtained through "liquid biopsies" can identify potentially important genomic alterations in patients for whom biopsy may be difficult in terms of risk or cost.
The presence of BRAF(V600E) mutation in PTC (show F9 Antibodies) confers a higher likelihood of FDG (show SMUG1 Antibodies) PET avidity and is associated with higher SUV uptake values compared to BRAF(V600E)-mutation negative status. [Review and Meta-Analysis]
CREB1 (show CREB1 Antibodies) may activate the transcription of wtBRAF through directly binding to its promoter, increasing BRAF expression and regulating the cell proliferation, migration and invasion of endometriosis.
A series of midline gangliogliomas demonstrate that the H3 K27M mutation can occur in association with the BRAF V600E mutation in grade I glioneuronal tumors. Despite the presence of H3 K27M mutations, these cases should not be graded and treated as grade IV tumors because they have a better spontaneous outcome than classic diffuse midline H3 K27M-mutant glioma.
In in vivo xenograft studies, BVD-523 showed dose-dependent growth inhibition and tumor regression. BVD-523 yielded synergistic antiproliferative effects in a BRAF(V600E)-mutant melanoma cell line xenograft model when used in combination with BRAF inhibition. Antitumor activity was also demonstrated in in vitro and in vivo models of acquired resistance to single-agent and combination BRAF/MEK (show MAP2K1 Antibodies)-targeted therapy
Proteomic analysis discovers that a novel E3 ligase, RNF44 (show RNF44 Antibodies), accounts for ubiquitin-proteasome system of AMPK (show PRKAA1 Antibodies)-alpha1 degradation in BRAF inhibitor-resistant melanoma cells.
common conjunctival melanocytic nevi have mutually exclusive mutations in BRAF and NRAS. The two conjunctival blue nevi harbored GNAQ mutations. This suggests the driver mutations of conjunctival nevi are similar to those of nevi of the skin. At the molecular level, conjunctival nevi appear more like cutaneous nevi than choroidal nevi
the mutational status of BRAF, NRAS (show NRAS Antibodies), and TERT (show TERT Antibodies) promoter genes in 97 melanomas, was investigated.
Coexistence of BRAF V600E mutation and EZH2 (show EZH2 Antibodies) gain is rather prevalent in melanoma.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (show TWIST2 Antibodies) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (show CDX2 Antibodies)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (show CDX2 Antibodies) silencing to alter gene expression. Like human serrated lesions, CDX2 (show CDX2 Antibodies)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (show SLITRK1 Antibodies) reduces copper levels and MAPK (show MAPK1 Antibodies) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (show ROCK2 Antibodies) form independent RAF1 (show RAF1 Antibodies) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (show EGF Antibodies)).
Braf(V600E) expression, coupled with simultaneous p53 (show TP53 Antibodies) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (show RAF1 Antibodies) operate independently to balance MAPK (show MAPK1 Antibodies) signaling: BRAF promotes ERK (show EPHB2 Antibodies) activation, while RAF1 (show RAF1 Antibodies) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (show PAX3 Antibodies).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein